Stem-cell-derived neurons show durable benefit in Parkinson's after three years

Published · Researched 2026-09-22

What happened (dated facts)

In 36-month results from the Phase 1 trial of bemdaneprocel — stem-cell-derived dopamine neurons transplanted into the brains of people with Parkinson's disease — the therapy showed no therapy- or surgery-related adverse events and durable motor improvements: high-dose participants improved by a mean of 17.9 points on the off-medication MDS-UPDRS Part III motor scale, and low-dose participants by 13.5 points, both clinically meaningful changes. Brain imaging confirmed the transplanted cells survived and continued producing dopamine even after immunosuppression was stopped at 12 months. These are company-reported results in a very small Phase 1 cohort (11–12 patients), so they are framed as promising safety-plus-signal data, not proof of efficacy.

Why it is genuinely positive

Replacing the dopamine neurons Parkinson's destroys — and having them survive, function, and improve movement three years later without ongoing immunosuppression — is the regenerative outcome the field has chased for decades. The durability at 36 months is what makes this more than a blip.

Social pulse

Strong biotech-press circulation of the 36-month Phase 1 results. Targeted Threads searches did not return direct posts about bemdaneprocel in this session. The social layer here is biotech media rather than viral patient posts.

Verified quotes

None captured.

Verification

• Tier: 2
• Primary source: BlueRock Therapeutics press release on the 36-month Phase 1 results (https://www.bluerocktx.com/bluerock-therapeutics-reports-positive-36-month-results-from-phase-i-trial-of-bemdaneprocel-for-treating-parkinsons-disease/), October 2025. Proves: 17.9-point (high dose) and 13.5-point (low dose) motor improvements; no therapy-related AEs; cell survival post-immunosuppression.
• Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
• Positivity check: durable motor improvement with a clean safety readout — genuine signal, with the company-reported/small-cohort caveat stated.

Key facts

UNVERIFIED points

• Social-layer posts about bemdaneprocel were not yet observed; tier cannot be finalized until they are.
• Results are company-reported from a small Phase 1 cohort; independent peer-reviewed publication was not verified this session.

Sources

• Primary source: BlueRock Therapeutics press release on the 36-month Phase 1 results ( — retrieval date not recorded